title: Elotuzumab: First Global Approval.
abstract: Elotuzumab (Empliciti™) is a humanised IgG1 monoclonal antibody developed by Bristol-Myers Squibb (BMS) and AbbVie that has been approved as combination therapy with lenalidomide and dexamethasone for relapsed/refractory multiple myeloma in the US. Elotuzumab binds to the cell surface receptor signalling lymphocytic activation molecule F7 (SLAMF7), which is selectively expressed on myeloma cells and natural killer cells, leading to antibody-dependent cellular cytotoxicity and direct natural killer cell activation. In a phase III clinical trial, addition of elotuzumab to lenalidomide and dexamethasone therapy in patients with relapsed/refractory multiple myeloma was associated with a significant improvement in progression-free survival and overall response rate. This article summarizes the milestones in the development of elotuzumab leading to this first approval for relapsed/refractory multiple myeloma.
authors.affiliation: Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.
authors.forename: Anthony
authors.initials: A
authors.lastname: Markham
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D011485:Protein Binding; D000071176:Signaling Lymphocytic Activation Molecule Family / Q000378:metabolism*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C448987:SLAMF7 protein, human; D000071176:Signaling Lymphocytic Activation Molecule Family; C546027:elotuzumab
references.citation: Blood. 2008 Aug 15;112(4):1329-37
references.pmid: 17906076
references.citation: Mol Cancer Ther. 2009 Sep;8(9):2616-24
references.pmid: 19723891
references.citation: Lancet Haematol. 2015 Dec;2(12 ):e516-27
references.pmid: 26686406
references.citation: N Engl J Med. 2015 Aug 13;373(7):621-31
references.pmid: 26035255
references.citation: Blood Cancer J. 2015 Aug 07;5:e334
references.pmid: 26252787
references.citation: Cancer Immunol Immunother. 2013 Dec;62(12 ):1841-9
references.pmid: 24162108
references.citation: Clin Cancer Res. 2008 May 1;14 (9):2775-84
references.pmid: 18451245
references.citation: J Clin Oncol. 2012 Jun 1;30(16):1960-5
references.pmid: 22291084
references.citation: Biomed Res Int. 2015;2015:341430
references.pmid: 26649299
references.citation: Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):129-38
references.pmid: 26795075